Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Statement from the RECOVERY trial chief investigators, 15 January 2021

John Curtis. Image courtesy of NHS Blood and Transplant.

Update on recruitment to convalescent plasma and tocilizumab treatment arms

Statement from the RECOVERY trial chief investigators, 11 January 2021

Leicester’s hospitals recruit over 1,000 patients for the RECOVERY trial

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on azithromycin, 14 December 2020

RECOVERY trial shortlisted for the National Project Awards 2020 Special COVID-19 response category

The RECOVERY trial has been selected as one of ten finalists in the Special COVID-19 response category in the 2020 National Project Awards, organised by PMI UK, in association with PricewaterhouseCoopers (PwC).

Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

RECOVERY trial clinicians can now be accredited through the Associate Principal Investigator Scheme

John Curtis. Image courtesy of NHS Blood and Transplant.

RECOVERY participant is first person to receive and donate convalescent plasma

Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

Update on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial

Statement on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial

Portrait of Lucy Fletcher

RECOVERY trial management acknowledged in clinical trial awards

Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19

RECOVERY COVID-19 phase 3 trial to evaluate Regeneron’s REGN-COV2 investigational antibody cocktail in the UK

One of the world’s largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2 on mortality, hospital stays, and the need for ventilation.

No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29 June 2020

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on dexamethasone, 16 June 2020

No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020

First patient, a child, receives convalescent plasma through RECOVERY, the dedicated COVID-19 treatment trial

Recruitment to the RECOVERY Trial continues as planned

RECOVERY team reflect on International Clinical Trials Day 2020

Load More